Legal entity
Every one of those 1 sits in a single category, corporate-law. semaglutide is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. We currently track 1 Legal story that mention semaglutide, all published on September 24, 2026.
Last mentioned: 3d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, corporate-law. semaglutide is most often covered alongside Eli Lilly, which appears in 1 of these 1 story. We currently track 1 Legal story that mention semaglutide, all published on September 24, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering semaglutide. Shared-story counts are live from our verified record — not editorial picks.
First NAION lawsuits filed against GLP-1 makers in New Jersey
Patients begin filing lawsuits alleging that GLP-1 drugs such as Ozempic, Wegovy, and Zepbound caused permanent vision loss and that manufacturers failed to warn about the risk.
Nearly 100 NAION lawsuits against Novo Nordisk and Eli Lilly test pharmaceutical failure-to-warn liability. Mixed epidemiological evidence and diabetes-related blindness risk create a dense causation battleground for mass tort litigators.
semaglutide is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
